Inspire Medical ($INSP) Cuts Guidance After Inspire V Reimbursement Issues Case
$INSP investors filed a claim against Inspire Medical Systems for allegedly misrepresenting the readiness and commercial success of its next-generation sleep apnea device, Inspire V. Plaintiffs claim the company concealed delays in training, billing integration, and reimbursement approval that materially undermined launch efforts.
After admitting in August 2025 that its Inspire V rollout faced adoption setbacks, insufficient clinician training, and poor demand, $INSP dropped 32% in one day.
$INSP investors can join this case to be notified about potential recovery.
Between August 6, 2024, and August 4, 2025, Inspire repeatedly told investors it was fully prepared to launch its new Inspire V sleep apnea device. Executives cited strong market demand, robust operational readiness, and adequate payer coverage. On multiple earnings calls and at investor conferences, management emphasized that the company had completed all regulatory and commercial prerequisites and expected the launch to drive meaningful growth in 2025.
However, according to the complaint, Inspire was facing serious challenges. Healthcare providers had large inventories of prior-generation devices, which limited demand for the newer model. Internally, many treatment centers had not completed required onboarding, clinician training, or billing system updates. Inspire also allegedly failed to ensure that Medicare billing codes were properly integrated prior to the full rollout—delaying reimbursement at many locations. Despite these issues, executives continued to characterize the rollout as “very positive” and “on track.”
On August 4, 2025, Inspire disclosed that the Inspire V launch was progressing slower than expected due to insufficient training at many treatment centers and unresolved billing delays tied to CPT code updates. The company also cited excess inventory and weaker-than-expected demand, and it cut full-year EPS guidance by more than 80%, from $2.20–$2.30 to just $0.40–$0.50.
Following the announcement, $INSP stock dropped $42.04 (32%), from $129.95 on August 4 to $87.91 on August 5, erasing approximately $1.2 billion in market value.
It misrepresented the readiness and adoption prospects of the Inspire V device.
It failed to disclose reimbursement delays and onboarding gaps at treatment centers.
It reaffirmed guidance that lacked a reasonable basis given internal rollout challenges.
Investors argue Inspire gave an overly optimistic picture of its Inspire V launch despite knowing that billing integration, training, and demand were materially below expectations.